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 This is the ﬁrst method for enantio-
meric proﬁling of chiral drugs
(cPACs) in solid & liquid matrices.
 Analysis of both liquid & solid matrix
is critical to do mass balance of cPACs
in wastewater.
 Chiral PACs are often non-racemic in
wastewater matrices.
 Enantiomeric composition of PACs
differs in liquid and solid wastewater
matrices.
 Not analysing the solid fraction of
wastewater may lead to over-estima-
tion of cPAC’s removal rates.
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A B S T R A C T
This is the ﬁrst study presenting a multi-residue method allowing for comprehensive analysis of several
chiral pharmacologically active compounds (cPACs) including beta-blockers, antidepressants and
amphetamines in wastewater and digested sludge at the enantiomeric level. Analysis of both the liquid
and solid matrices within wastewater treatment is crucial to being able to carry out mass balance within
these systems. The method developed comprises ﬁltration, microwave assisted extraction and solid
phase extraction followed by chiral liquid chromatography coupled with tandem mass spectrometry to
analyse the enantiomers of 18 compounds within all three matrices. The method was successfully
validated for 10 compounds within all three matrices (amphetamine, methamphetamine, MDMA, MDA,
venlafaxine, desmethylvenlafaxine, citalopram, metoprolol, propranolol and sotalol), 7 compounds
validated for the liquid matrices only (mirtazapine, salbutamol, ﬂuoxetine, desmethylcitalopram,
atenolol, ephedrine and pseudoephedrine) and 1 compound (alprenolol) passing the criteria for solid
samples only. The method was then applied to wastewater samples; cPACs were found at concentration
ranges in liquid matrices of: 1.7 ng L1 (metoprolol) – 1321 ng L1 (tramadol) in inﬂuent, <LOD
(desmethylcitalopram and metoprolol) – 506 ng L1 in efﬂuent, and in solid matrix digested sludge:
0.4 ng g1 (metoprolol) – 275 ng g1 (citalopram). Enantiomeric proﬁling revealed that studied
compounds were present in analysed samples in non-racemic composition. Furthermore, enantiomeric
composition of studied analytes differed in liquid and solid matrices. This demonstrates that not
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ACA 233825 No. of Pages 15analysing the solid fraction of wastewater may lead to over-estimation of the removal rates of cPACs as
well as possible misrepresentation of the enantiomeric fraction of the compounds as they leave the
wastewater treatment plant. Consequently risks from cPACs entering the environment might be higher
than anticipated.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Developments in pharmacology and an ageing population have
led to a steady increase in the prescription of pharmaceuticals
worldwide. Once metabolised and excreted pharmacologically
active compounds (PACs) and their metabolites enter the sewage
system and if not removed or degraded, they are then pumped into
efﬂuent receiving water bodies and/or are incinerated or spread on
agricultural land if adsorbed on to solids.
Pharmaceuticals and illicit drugs are routinely identiﬁed in
wastewater. The data produced is often used to inform risk
assessments [1,2] and develop and test prediction models [3].
However, these concentrate on pharmacologically active com-
pounds (PACs) present in the aqueous matrix and they do not
consider the fraction of PACs adsorbed on to the sediments and
suspended solids which may still be bioavailable to organisms and/
or may desorb in the future, possibly due to a change in matrix or
environmental conditions. Methods have been developed recently
in order to tackle this knowledge gap and to verify concentration
levels of PACs in sediments [4–8], sludge [7], colloids [9], settable
particulate matter [10] and suspended matter [6,11] as well as
other solid matrices such as soil [12]. Corresponding models have
also emerged to take into account this additional data [13].
Many PACs, prescribed, over the counter and illicit, are chiral.
Enantiomers often have widely disparate pharmaco-dynamics
and -kinetics in humans [14]. This may result in the excreted
parent drug and/or metabolites having a different enantiomeric
composition to the ingested drugs [14]. The fate of chiral PACs
(cPACs) within the environment can be affected by micro-
organisms and this process has been shown to be, at least in part,
stereoselective. The enantiomeric composition of cPACs has also
been demonstrated to be signiﬁcant in the toxicity of several
environmentally relevant species. S(+)-ﬂuoxetine and S()-aten-
olol were found to signiﬁcantly inhibit the growth of Tetrahyme-
na thermophila, a freshwater protozoan, more than R
()-ﬂuoxetine and R(+)-atenolol. Whilst R(+)-atenolol increased
mortality rates in Pseudokirchneriella subcapitata, an algae,
signiﬁcantly more than S()-atenolol [16]. Stanley et al. [17,18]
have also demonstrated enantiomer selective toxicity in ﬂuoxe-
tine and propranolol towards Pimephales promelas and fathead
minnow, with S(+)-ﬂuoxetine and S()-propranolol being the
more toxic enantiomers [17,18]. All three of these studies also
exposed Daphnia magna to the enantiomers of atenolol, ﬂuoxetine
and propranolol but found no enantioselective toxicity towards
this species.
Consequently, in more recent years, attention has been placed
on the veriﬁcation of enantiomeric composition of cPACs within
wastewater and the efﬂuent receiving waters [19–34]. However,
these studies all concern themselves with the liquid fraction of the
environment. Only one study has extracted and quantiﬁed
antifungals from wastewater solid material [35]. This gap in the
methodology may result in an under estimation of the effects of
cPACs within an aquatic environment, if they adsorb to solid
material. It may also be the case that bacterial populations
associated with the solid material, and the process under which it
is digested at wastewater treatment plants (WWTPs), may alter the
enantiomeric fraction compared to both what it was on solid
material in the inﬂuent as well as what is currently being recordedPlease cite this article in press as: S.E. Evans, et al., Determination of chi
microwave assisted extraction, solid-phase extraction and chiral liquid ch
Acta (2015), http://dx.doi.org/10.1016/j.aca.2015.03.039in the liquid fraction. Therefore, it is of the greatest importance to
develop analytical capability to undertake stereoselective analysis
of chiral compounds in solid matrices.
This study aims to develop a novel comprehensive analytical
method for multi-residue identiﬁcation and quantiﬁcation of
23 cPACs (including several beta-blockers, antidepressants and
amphetamines, Table S1) at enantiomeric level in both the liquid
and solid fractions of wastewater. To the authors knowledge, such a
method has never been previously reported. It is anticipated that
this technique could then be validated and adapted for other solid
matrices such as biological matrices and soils where these PACs
may also be found due to, for example, the disposal of digested
sludge on agricultural land. The targeted analytes have been
identiﬁed based on high prescription/consumption rates within
the UK, widespread environmental occurrence and biological
effects, their chirality and the ability to resolve enantiomers via
chiral HPLC.
2. Materials and methods
2.1. Chemicals and materials
The reference standards: R/S ()-amphetamine, R/S ()-meth-
amphetamine, R/S ()-MDA (3,4-methylenedioxyamphetamine)
and R/S ()-MDMA (3,4-methylenedioxy-methamphetamine),
were purchased from LGC Standards (Teddington, UK); 1R,2S
(+)-ephedrine, 2R,2S ()-ephedrine, 1S,2S (+)-pseudoephedrine,
2S,2S ()-pseudoephedrine, R/S ()-norephedrine and
R/S ()-venlafaxine, R/S ()-ﬂuoxetine, R/S ()-norﬂuoxetine,
R/S ()-O-desmethylvenlafaxine, 1R,2R/1S,2S ()-tramadol, R/S
()-atenolol, R/S ()-metoprolol and R/S ()-propranolol, R/S
()-alprenolol, R/S ()-sotalol, R/S ()-salbutamol, R/S ()-mirta-
zapine, R/S ()-citalopram, R/S ()-mexiletine, R/S ()-terbuta-
line, were purchased from Sigma–Aldrich (Gillingham UK). R/S
()-MDEA (3,4-methylenedioxy-N-ethyl-amphetamine) was pur-
chased from LGC (Middlesex, UK) and R/S ()-desmethylcitalo-
pram was purchased from TRC (Toronto, Canada). All solvents were
of HPLC grade and were purchased from Sigma–Aldrich. All
glassware was silanised with dimethylchlorosilane (5% DMDCS in
toluene, Sigma–Aldrich) to minimise sample loss through adsorp-
tion of basic analytes onto OH sites present on the glass surface.
The surrogate/internal standards (SS/IS): R/S ()-amphetamine-
d11, R/S ()-methamphetamine-d14, R/S ()-MDMA-d5, R/S
()-MDA-d5 were purchased from LGC standards (Middlesex,
UK), whilst R/S()-atenolol-d7 were purchased from Sigma–
Aldrich (Gillingham, UK). R/S()-propranolol-d7, R/S()-metopro-
lol-d7, R/S()-sotalol-d6, R/S()-salbutamol-d6 were purchased
from TRC (Toronto, Canada). Stock solutions of each compound
(1 mg mL1) were prepared in methanol and stored in the dark at
16 C. Working solutions were prepared by diluting the stock
solution in mobile phase, and storing them at 16 C. Solid phase
extraction was carried out with the use of a vacuum manifold
(Sigma–Aldrich, UK). Oasis 60 mg MCX, 60 mg MAX and HLB 60 mg
cartridges were purchased from Waters (Waters, UK). Samples
were eluted into silanised borosilicate glass tubes (12  75 mm)
(Fisher, UK) and evaporated with a turbovap LV concentration
workstation (Caliper, UK). Solid matrix samples were extracted
using a MARS 6 microwave (CEM, UK).ral pharmaceuticals and illicit drugs in wastewater and sludge using
romatography coupled with tandem mass spectrometry, Anal. Chim.
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Digested cake and grab wastewater samples were collected in a
single visit to a UK wastewater treatment plant, whose character-
istics are shown in Table S2. They were transported back to the
laboratory in cool boxes packed with ice blocks and frozen
immediately upon arrival. All inﬂuent, efﬂuent and digested sludge
samples were collected simultaneously and therefore should not
be interpreted as representing the same body of water. The cake
was frozen, then dry frozen (Scanvac dryer, Scientiﬁc Laboratory
Supplies, UK) and stored at 20 C. Wastewater was also stored at
20 C.
2.2.1. Microwave assisted extraction (MAE) for solid matrix
Method development for MAE ﬁrstly identiﬁed conditions
which had been reported as successful within the literature for
related compounds, methods and matrices. Mass of sample,
solvent volume and type, temperature and exposure time as well
as pH were identiﬁed as crucial parameters. Table 1 summarises
the iterations trialled.
The following conditions resulted in the most effective MAE
recovery: 20 mL methanol:water (1:1), heated to 120 C for 30 min.
Both 1 g and 3 g of freeze-dried sample were used for method
validation purposes.
2.2.2. Solid-phase extraction (SPE)
2.2.2.1. SPE for liquid matrix. The wastewater samples (50 mL)
were ﬁltered and then spiked with SS/IS (1 mg L1) before being
passed through Oasis HLB cartridges, with reversed phase sorbent,
conditioned with 2 mL methanol, followed by 2 mL deionised
water and eluted in 4 mL methanol.
2.2.2.2. SPE for solid matrix. Method development for the solid
matrix SPE included trialling 3 types of SPE adsorbents (Table 2).
Initially Oasis HLB 60 mg cartridges were used in accordance with
the liquid matrix methodology described above, with the sample
eluent diluted to no more than 10% methanol.
MCX cartridges were also trialled using a method previously
successful in non-chiral analysis of pharmaceuticals on suspended
particulate matter [11], these are packed with a mixed-mode
polymeric sorbent for extracting basic compounds with cation-
exchange groups. In brief, cartridges were primed with 2% formic
acid in water, and after extraction of cPACs from wastewater they
were washed with 2% formic acid in water and then again with 0.6%
formic acid in water prior to elution with 7% ammonium hydroxide
in methanol.
Following this, Oasis MAX cartridges were trialled, using the
same methodology as the HLB cartridges described above. These
are packed with a mixed-mode polymeric sorbent for extracting
acidic compounds with anion-exchange groups.
In all cases, the sample (wastewater or MAE extract) was
deposited on the SPE cartridges at a rate of <6 mL min1, eluents
were evaporated to dryness with a TurboVap evaporator (Caliper,
UK, 40 C, N2, <5 psi) and reconstituted in 0.5 mL of mobile phase.Table 1
MAE method development.
Parameter Iterations trialled
Mass 1 g, 3 g
Solvent type Methanol, water, methanol:water (1:1)
Solvent volume 10, 20, 50 mL
Temperature 90, 120, 150 C
Exposure time 15, 30 min
Please cite this article in press as: S.E. Evans, et al., Determination of chir
microwave assisted extraction, solid-phase extraction and chiral liquid ch
Acta (2015), http://dx.doi.org/10.1016/j.aca.2015.03.039All samples were ﬁltered through 0.2 mm PTFE ﬁlters (Whatman,
Puradisc, 13 mm) and transferred to 0.5 mL capacity polypropylene
vials (Waters, UK).
2.3. LC–MS/MS
All samples were analysed using chiral HPLC performed on
Waters ACQUITY UPLC1 system (Waters, UK). The chiral separation
was carried out with two columns: CBH, an enzyme based column
packed with Cellobiohydrolase (100  2 mm, I.D. 5 mm,
Sigma–Aldrich, UK) with a 0.2 mm, 2.1 mm in-line column ﬁlter,
and Chirobiotic V (250  2.1 mm, I.D. 5 mm, Sigma–Aldrich, UK)
packed with an antibiotic Vancomycin with a 20  1.0 mm, I.D.
5 mm guard column.
The CBH column is relatively restrictive regarding mobile phase
composition e.g. no more than 20% organic modiﬁer is recom-
mended and pHs between 3 and 7 are allowed [36]. However, it
shows the best chiral recognition towards amphetamine-related
compounds. A successful method for the resolution of amphet-
amines has already been developed by Kasprzyk-Hordern and
Baker [20] and it was utilised in this work without any further
development.
Method development was carried out for the Chirobiotic V
column. This column can be used in reverse or normal phase,
however previous results [28] had elicited resolution of enan-
tiomers in some of the target compounds with methanol, 0.005%
formic acid and 4 mM ammonium acetate so this mobile phase
composition was used as the basic method to improve upon,
iterations trialled are included: proportion of water (0, 2.5, 5, 7.5,
10, 20%), ammonium acetate (1, 2, 4, 6, 8,10, 20, 30 mM) and formic
acid (0, 0.001, 0.0025, 0.005, 1 and 2%).
The best enantiomeric separation and sensitivity were observed
in the following conditions: methanol, 4 mM ammonium acetate
and 0.005% formic acid.
All analytes were identiﬁed and quantiﬁed using a Xevo TQD
Triple Quadrupole Mass Spectrometer (Waters, UK), equipped
with an electrospray ionisation source in positive ion mode.
Nitrogen was used as the nebulising gas, supplied by a high purity
nitrogen generator (Peak Scientiﬁc, UK). Argon (99.998%) was the
collision gas supplied by a BOC cylinder. MassLynx 4.1 (Waters,
UK) was used to control the Waters ACQUITY system and the Xevo
TQD. Data processing was carried out using the TargetLynx
software (Waters, UK). A valley drop method was used to
integrate partially resolved peaks. The sensitivity was monitored
whilst adjusting the nebulising gas ﬂow rate to 100, 250 and
500 L h1 as well as the source temperature between 90 and
250 C to achieve the greatest sensitivity with the chosen mobile
phase, each injection was 20 mL. Optimised MS parameters were
as follows: the capillary voltage set at 3.49 kV, source tempera-
ture at 150 C, desolvation gas ﬂow at 300 L h1. Nitrogen was
used as nebulising and desolvation gas, while argon was used as a
collision gas.
2.4. Quantiﬁcation and conﬁrmation
Each compound was quantiﬁed in multiple reaction moni-
toring (MRM mode), using the protonated molecular ion as the
precursor ion (Table 3). The most abundant product ion was
used for quantiﬁcation (in most cases), whilst conﬁrmation was
carried out using the lesser (second) abundant product ion. In
addition the ratio of quantiﬁer to conﬁrmatory ion was used
according to limits set by EC guidelines [37] i.e. ratios
50%  20%, >20–50%  25%, >10–20%  30% and 10%  50%.
Deuterated surrogate/internal standards (SS/IS) were used to
compensate for ion suppression/enhancement, loss duringal pharmaceuticals and illicit drugs in wastewater and sludge using
romatography coupled with tandem mass spectrometry, Anal. Chim.
Table 2
SPE conditions trialled.
SPE sorbent Eluting agent pH Comments
HLB Methanol 7 High back pressure in LC column
MCX Ammonium hydroxide 12 Poor chromatography
MAX Methanol 7 No high back pressure, good chromatography
Table 3
MRM conditions.
Drug CV MRM (Q) CE
(Q)
MRM (I) CE
(I)
IQ:I
Alprenolol 44 250.0 > 115.9 16 250.0 > 97.9 18 0.4
Amphetamine 18 136.2 > 91.1 16 136.2 > 119.1 8 1.0
Atenolol 38 266.9 > 145.0 30 266.9 > 190.1 16 1.2
Citalopram 46 325.1 > 262.1 18 325.1 > 109.9 26 0.9
Desmethylcitalopram 46 311.4 > 109.0 27 311.4 > 262.0 18 3.4
Desmethylvenlafaxine 32 264.2 > 106.9 34 264.2 > 133.0 26 0.5
Ephedrine/
pseudoephedrine
23 166.1 > 148.1 12 166.1 > 133.1 21 1.0
Fluoxetine 34 310.2 > 44.0 10 310.2 > 148.1 10 16.7
MDA 21 180.0 > 163.1 11 180.0 > 105.1 22 3.8
MDEA 18 209.0 > 164.0 12 209.0 > 164.0 20 4.5
MDMA 24 194.1 > 163.1 13 194.1 > 105.1 24 2.6
Methamphetamine 24 150.2 > 91.1 19 150.2 > 119.1 10 1.5
Metoprolol 42 268.3 > 116.1 20 268.3 > 121.1 22 2.6
Mexiletine 26 180.0 > 104.9 20 180.0 > 120.9 16 2.2
Mirtazapine 44 266.1 > 195.0 26 266.1 > 72.0 18 1.0
Norephedrine 23 152.2 > 134.1 10 152.2 > 117.1 16 1.0
Norﬂuoxetine 56 296.3 > 134.1 6
Propranolol 40 260.0 > 183.3 18 260.0 > 116.8 16 136.3
Salbutamol 30 240.1 > 148.0 18 240.1 > 166.0 14 0.3
Sotalol 30 272.9 > 133.0 28 272.9 > 212.9 18 0.8
Terbutaline 66 226.1 > 76.9 32 226.1 > 152.0 24 2.4
Tramadol 28 264.0 > 58.0 45 264.0 > 120.7 46 10.6
Venlafaxine 27 278.2 > 260.1 12 278.2 > 121.0 32 1.6
Amphetamine-d5 18 141.0 > 92.9 16
Atenolol-d7 44 274.3 > 145.1 30
Citalopram-d6 46 331.0 > 109.0 28
Fluoxetine-d5 26 315.2 > 136.2 20
MDA-d5 21 185.1 > 168.1 11
MDEA-d5 18 214.0 > 164.0 12
MDMA-d5 24 199.1 > 165.1 13
Methamphetamine-d5 24 155.0 > 121.0 11
Metoprolol-d7 42 275.4 > 123.1 20
Mirtazapine-d7 30 273.0 > 209.1 19
Propranolol-d7 42 267.3 > 123.2 18
Salbutamol-d9 51 249.5 > 231.0 12
Sotalol-d6 32 279.0 > 134.2 36
CV – cone voltage; CE – collision energy; IQ:I – ion ratio.
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sample preparation; where exact deuterated matches were not
available, the closest match (both in retention time and
structure) was substituted.
2.5. Validation of analytical method
2.5.1. Validation of instrumental parameters – LC–MS/MS method
Linearity of analytical methods was determined using a
15 point calibration curve for each enantiomer ranging from
0.025 mg L1 to 250 mg L1, injected three times. Linearity was
accepted if the curve demonstrated R2 0.997. Interday and
intraday precision and accuracy was determined at 0.5 mg L1,
5 mg L1, 50 mg L1 and 250 mg L1, by repeated injection within
24 h and across three days, respectively. Acceptable tolerance
limits were placed at the EC guideline levels [37] i.e. for
concentrations 10–100 mg L1 the RSD 20%, for standards
>100 mg L1 RSD 15%, and accuracy should not exceed 20% or
+10% of the standard concentration. Instrumental detection limits
(IDLS/N) and instrumental quantiﬁcation limits (IQLS/N) were
calculated using the signal to noise approach i.e. IDL was the
lowest concentration at which the quantiﬁcation ion
S/N  3 assuming a linear response, IQL was the lowest concen-
tration at which the quantiﬁcation ion S/N  10 and the
conﬁrmatory ion S/N  3 assuming a linear response.
Resolution was calculated using Eq. (1),Rs 1 was deemed
adequate for quantiﬁcation. Enantiomeric fraction (EF) was
calculated using Eq. (2), EF accuracy was considered acceptable
if 0.05 of the true value. Retention times were recorded and
relative retention times were also calculated (see Eq. (3)).
Rs ¼ tr2  tr10:5ðw1 þ w2Þ (1)
where Rs is the resolution of two enantiomers, tr2 is the retention
time of the second eluting enantiomer, tr1 is the retention time of
the ﬁrst eluting enantiomer, w1 is the base width of the ﬁrst eluting
enantiomer, w2 is the base width of the second eluting enantiomer.
EF ¼ E1
E1 þ E2 (2)
where EF is the enantiomeric fraction. When calculating relative
enantiomeric fractions, E1 is the concentration of (+)-enantiomer
or ﬁrst eluted enantiomer, E2 is the concentration of ()-enantio-
mer or second eluting enantiomer. Peak areas were also used
instead of concentrations to calculate absolute enantiomer
fractions (not adjusted with surrogate/standard).
trrel ¼
tr
IStr
(3)
where tr rel is the relative retention time, tr is the retention time
recorded for the analyte, IS tr is the retention time recorded for the
internal standard.
2.5.2. Validation of analytical method – MAE-SPE-LC-MS/MS method
The method was validated at 5 ng g1, 50 ng g1 and 100 ng g1
of target analytes (each enantiomer) for digested sludge, and
5 ng L1, 50 ng L1 and 250 ng L1 in wastewater. At eachPlease cite this article in press as: S.E. Evans, et al., Determination of chi
microwave assisted extraction, solid-phase extraction and chiral liquid ch
Acta (2015), http://dx.doi.org/10.1016/j.aca.2015.03.039concentration triplicate samples were either spiked before MAE,
before SPE or after SPE to assess the impact of these steps on
analyte recovery. This was carried out on 1 g and 3 g of matrix or
50 mL of wastewater. Sludge and wastewater samples were also
run with only deuterated compounds to assess concentrations of
target analytes in studied matrices.
In addition, the relative ion intensities were assessed according
to the EC Directive guidelines [37] i.e. for relative intensities
50%  20%, >20% to 50%  25%, >10% to 20%  30%, 10%  50%.
Resolution, enantiomeric fractions and relative retention times
were calculated, using Eqs. (1)–(3), for three whole drug
concentrations (10 ng L1, 100 ng L1, 500 ng L1 in the case of
wastewater or 10 ng g1, 100 ng g1 or 200 ng g1 for sludge) spiked
into wastewater inﬂuent, efﬂuent and digested sludge. Method
detection limits (MDLs) and method quantiﬁcation limits (MQLs)
were determined using Eqs. (4)–(7). The IDLS/N, IQLS/Nwere used to
generate MDLcalc and MQLcalc.ral pharmaceuticals and illicit drugs in wastewater and sludge using
romatography coupled with tandem mass spectrometry, Anal. Chim.
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where S.IDL is the IDLS/N multiplied by the solvent volume used,
in this case 30 mL, divided by the mass of matrix used, in this case
1 or 3 g. Av.Rec is the average absolute recovery for that
compound. The concentration factor is the ratio between the
initial volume (30 mL) and the ﬁnal volume in mobile phase, in
this case 0.5 (mL), therefore CF = 60. The discarded fraction is to
compensate for taking a known volume post centrifugation; in
this case 50% was discarded so the concentration factor is
multiplied by 2.
MQLMAE-SPE-LC-MS=MS ¼ S:IQL  100Av:Rec  ðCF  discarded fractionÞ (5)
This equation is set out the same as Eq. (4), however the S.IQL is the
IQLS/N multiplied by the solvent volume used, in this case 30 mL,
divided by the mass of matrix used, in this case 1 or 3 g.
MDLSPE-LC-MS=MS ¼ IDL  100Av:Rec  CF (6)
where Av. Rec is the average absolute recovery recorded and CF is
the concentration factor between the sample taken and the ﬁnal
volume in mobile phase, in this case 50–0.5 mL so CF = 100.
MQLSPE-LC-MS=MS ¼ IQL  100Av:Rec  CF (7)
This is set out the same as Eq. (6).
Analyte recovery was calculated using Eq. (8) by comparing the
initial spike concentration with the measured concentration after
extraction and analysis. Known concentrations of racemic stand-
ards were applied to the liquid matrices before SPE and also after
SPE, whereas solid matrix samples were spiked before MAE and
after MAE (before SPE) to identify the analyte recovery associated
with each step of the process.Fig. 1. MAE–SPE-chiral LC–MS/MS for c
Please cite this article in press as: S.E. Evans, et al., Determination of chir
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 
 100 (8)
where PASPE is the peak area of an analyte from the sample spiked
before SPE, PAb is the peak area of the (unspiked) blank sample, PAc
is the peak area from the quality control sample (at the same
concentration of that which PASPE was spiked at). Alternatively,
concentrations were also used, instead of peak areas, to calculate
relative recoveries.
2.6. Analysis of wastewater samples
Grab samples were collected from the inﬂuent, efﬂuent and
digested sludge at the WWTP. The liquid grab samples were
collected in a clean container and transferred to plastic bottles for
transportation, on ice, and storage, at 20 C. Digested sludge was
collected in a plastic sampling bag, sealed and transported and
stored under the same conditions as the liquid matrices. All the
samples were collected at the same time and should not be
interpreted as the same body of waste. The validated analytical
procedures described in Section 3 and shown in Fig.1, were applied
to samples prepared in triplicate, which were then injected and
analysed in triplicate.
3. Results and discussion
3.1. Sample preparation
3.1.1. Microwave assisted extraction for solid matrix
MAE was demonstrated to successfully extract the chosen
analytes from complex matrices such as digested sludge. In brief,
increased temperature did appear to improve recovery with
complex matrices from an average recovery across all the
compounds analysed of 22.5% at 90 C for 30 min to 37.4% recovery
at 120 C. Although interestingly initial trials using silica as ahiral PACs – analytical procedure.
al pharmaceuticals and illicit drugs in wastewater and sludge using
romatography coupled with tandem mass spectrometry, Anal. Chim.
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ACA 233825 No. of Pages 15matrix found lower temperatures performed better, 120 C for
30 min resulted in 50.6% recovery with 90 C resulting in 102%.
With both matrices 150 C resulted in lower recoveries for some
compounds, with an average recovery of only 51% in silica,
suggesting degradation was occurring at this temperature. For
complex matrices 120 C was the most successful temperature. At
120 C, as well as lower temperatures, 30 min extraction time had
improved recovery as compared to 15 min, 37% and 29%,
respectively.
The mass of the sample did not appear to have a great effect on
the recovery. In the case of analysis of samples where lower
concentrations are expected, 3 g of matrix would be suggested to
improve the MDL; however, 3 g of matrix is more difﬁcult to
process. After centrifugation a semi-solid hydrophobic layer was
formed between the solid matrix and the solvent, whilst the dry
matrix also absorbed the solvent; a larger mass of sample
increased these challenges making it difﬁcult to decant a known
volume for SPE. Therefore, 1 g was preferred for this method.
Compounds with lower log P values tended to be best extracted
with 1:3 methanol:water mixture, amphetamine based com-
pounds average recovery was 101% at 1:3 methanol:water and 91%
at a ratio of 1:1; however, this had a signiﬁcant effect on the
recovery of more hydrophobic compounds, with recoveries of the
anti-depressants falling from 80% to 34%. Therefore, a 1:1 mixture
was settled upon as this had limited impact on the recovery of the
more hydrophilic compounds. In general it was found the less
solvent used the better the recovery, however, the difference was
minimal (1 g with 10 mL had an average recovery of 30% and with
30 mL 27%) and less solvent made it considerably harder to cleanly
remove the known volume for SPE without disturbing the matrix
and/or removing the hydrophobic layer on top of it. It was decided
that 30 mL of solvent was the lowest volume which could be used
consistently with both 3 g and 1 g of matrix.
The ﬁnal method is as follows (Fig. 1): replicates of digested
sludge (1 g each), after being spiked with SS/IS (at concentration
1 mg g1), were placed into the MAE tubes with 15 mL of methanol
and 15 mL deionised water and microwaved (CEM 1400 microwave,
CEM, UK) between 0 W and 1200 W to allow for a controlled ramp
to 120 C, this was held for 30 min before allowing to cool to room
temperature. The samples were transferred to a centrifuge, the
MAE tubes were rinsed out with 10 mL of deionised water, which
was added to the centrifuged containers. The samples were then
centrifuged (VWR, Radnor, USA) for 15 min at 4800 rpm. A ﬁxed
volume (20 mL) of solvent was decanted and diluted with 65 mL of
deionised water ready for SPE.
If analysis of individual chiral drugs was to be carried out,
solvents, exposure time etc. could be tailored more to speciﬁc
analytes, however, a compromise was made here to ensure
extraction of the widest range of analytes possible.
3.1.2. Solid phase extraction
3.1.2.1. SPE for MAE extracts. The chromatography was successful
when Oasis HLB cartridges were used after MAE (for solid matrix),
i.e. resolution of enantiomers was sufﬁcient for quantiﬁcation (see
Fig. S1a), however, the backpressure recorded in the column
increased with each subsequent injection, (see Fig. S2). This was
not observed in the case of liquid matrices where extraction with
HLB was carried out. This back pressure increase suggested matrix
clean-up by SPE using Oasis HLB cartridges had not been sufﬁcient
for MAE extracts and interfering compounds were retained on the
chiral LC column causing the increased backpressure.
MCX sorbents were also found to be successful in removing the
interfering compounds (from MAE extracts) which had been
retained in the column, and therefore no increase in backpressure
was observed, however, cPACs have to be eluted from MCXPlease cite this article in press as: S.E. Evans, et al., Determination of chi
microwave assisted extraction, solid-phase extraction and chiral liquid ch
Acta (2015), http://dx.doi.org/10.1016/j.aca.2015.03.039cartridges in methanol modiﬁed with ammonium hydroxide.
Despite evaporation and re-elution in mobile phase the high pH
resulted in very poor resolution for all the compounds as well as
loss of chiral recognition (see Fig. S1b). This has been demonstrated
not to be an issue for C18 stationary phase and non-chiral reversed
phase chromatography [11], however, chiral columns are particu-
larly sensitive to even small pH changes and the presence of
charged molecules in the mobile phase impacts on both retention
time and resolution of enantiomers.
MAX cartridges proved to be the most effective when coupled
with chiral LC–MS. Despite low recoveries, good chromatographic
separation of enantiomers was achieved and no build-up of back
pressure was observed (see Fig. S1c).
The optimised method for the extraction of analytes from MAE
extracts is therefore as follows (Fig. 1): 20 mL of MAE centrifuged
supernatant, diluted with 65 mL of deionised water, was passed
through Oasis MAX cartridge pre-conditioned with 4 mL of
methanol followed by 4 mL of deionised water and eluted with
4 mL methanol.
3.1.2.2. SPE for liquid matrix. Oasis HLB cartridges provided
successful extraction of analytes from wastewater. The method
involved ﬁltering 50 mL wastewater samples (GF/F, Whatman, UK)
then spiking with SS/IS (1 mg L1). These were then passed through
Oasis HLB cartridges, conditioned with 2 mL methanol, followed by
2 mL deionised water and eluted in 4 mL methanol (Fig. 1).
However, it has to be remembered that this method, due to the use
of GF/F ﬁlters, allows for the measurement of the analytes present
in the liquid phase of wastewater and not any compounds
adsorbed onto suspended particulate material (SPM). Previous
analysis of SPM suggests that the amphetamine based compounds,
venlafaxine and tramadol, are not signiﬁcantly bound to SPM
(3.4% of the total concentration was found on SPM), however,
ﬂuoxetine was largely found on the SPM (59.1% of the total
concentration) so further analysis of SPM is required to determine
an accurate whole matrix concentration [11].
3.2. LC–MS/MS
3.2.1. Chiral LC–MS/MS with CBH column
The method for separation of enantiomers on the CBH column
was used as reported elsewhere (Kasprzyk-Hordern and Baker
[21]). Separation was undertaken using isocratic conditions, with a
mobile phase of 90% H2O, 10% 2-propanol and 1 mM ammonium
acetate at a ﬂow rate of 0.075 mL min1. The column was
maintained at 25 C and the injection volume was 20 mL (Fig. 1).
The following compounds were separated with this column:
amphetamine, MDA, MDMA, methamphetamine, ephedrine/pseu-
doephedrine and norephedrine (Figs. S6–8).
3.2.2. Chiral LC–MS/MS with Chirobiotic V column
Increased water content in the mobile phase increased elution
of the compounds, however, also decreased the signal to noise ratio
and the enantiomeric resolution in most compounds, with the
notable exception of norﬂuoxetine. Increased ammonium acetate
concentration increased the retention times of most compounds
and with up to 10 mM the resolution was also improved, however,
no compounds which were previously below the quantiﬁcation
threshold (resolution  1) improved enough to become quantiﬁ-
able. Retention times and resolution were best at 0.001% formic
acid, but again none of the compounds whose resolution was too
poor to quantify became quantiﬁable between 0.001 and 0.005%.
There was no trend related to signal to noise for ammonium
acetate and formic acid at these concentrations. Therefore, the ﬁnal
mobile phase composition chosen for the Chirobiotic V columnral pharmaceuticals and illicit drugs in wastewater and sludge using
romatography coupled with tandem mass spectrometry, Anal. Chim.
Table 4
Performance data for LC–MS/MS method – sample diluent.
Column Compound Internal standard R2 tr tr rel Rs EFabs EFrel Accuracy Precision
RSD (%)
Ion ratio IDLS/N (mg L1) IQLS/N (mg L1)
Intra-day Inter-day
CBH R()-amphetamine R()-amphetamine-d5 0.998 24.40.5 1.00.0 2.10.4 0.40.0 0.50.0 95.76.4 2.6 3.3 94.213.0 0.30 1.01
S(+)-amphetamine S(+)-amphetamine-d5 0.998 30.20.5 1.00.0 95.75.9 3.2 3.3 90.411.5 0.34 1.14
1S,2R(+)-ephedrine R()-methamphetamine-d5 0.997 21.10.2 1.20.0 1.80.4 0.60.2 0.50.1 102.43.9 4.0 3.8 9.21.1 0.97 3.24
1R,2S()-ephedrine S(+)-methamphetamine-d5 0.997 24.00.2 1.10.0 102.93.0 2.3 2.8 8.82.6 1.83 6.11
R()-MDA R()-MDA-d5 0.999 39.80.7 1.00.0 4.51.2 0.50.2 0.50.0 97.24.8 1.3 1.8 26.72.1 0.27 0.91
S(+)-MDA S(+)-MDA-d5 0.999 51.20.7 1.00.0 97.64.6 2.0 2.5 26.42.1 0.31 1.03
R()-MDEA R()-MDEA-d5 0.997 35.60.8 1.00.0 0.60.1 0.50.1 0.50.0 94.66.8 4.4 6.2 25.15.0 0.25 0.83
S(+)-MDEA S(+)-MDEA-d5 0.997 37.50.8 1.00.0 94.95.2 2.9 3.8 27.311.7 0.25 0.82
R()-MDMA R()-MDMA-d5 0.998 35.10.7 1.00.0 1.70.3 0.50.1 0.50.0 95.14.5 2.0 2.2 34.96.3 0.05 0.17
S(+)-MDMA S(+)-MDMA-d5 0.998 42.40.8 1.00.0 95.84.3 2.2 2.5 34.85.8 0.05 0.18
R()-methamphetamine R()-methamphetamine-d5 0.998 25.10.6 1.00.0 1.00.1 0.50.2 0.50.0 97.55.5 3.7 3.9 68.47.2 0.10 0.32
S(+)-methamphetamine S(+)-methamphetamine-d5 0.998 28.10.7 1.00.0 97.55.0 3.8 3.9 66.95.9 0.11 0.35
E1- norephedrine R()-methamphetamine-d5 0.997 21.70.2 1.20.0 0.90.1 0.50.0 0.50.1 102.33.4 3.9 3.3 4.60.9 1.64 5.47
E2- norephedrine S(+)-methamphetamine-d5 0.997 23.40.2 1.20.0 102.75.1 4.9 5.4 4.71.2 1.63 5.42
1R,2R()-pseudoephedrine R()-methamphetamine-d5 0.997 22.40.1 1.10.0 2.80.8 0.50.1 0.50.0 103.45.2 4.1 5.3 9.42.2 1.38 4.60
1S,2S(+)-pseudoephedrine R()-methamphetamine-d5 0.997 27.50.3 1.00.0 103.14.3 4.4 4.3 8.52.0 1.46 4.85
Chirobiotic V S()-alprenolol S()-metoprolol-d7 0.998 25.20.3 0.90.0 1.30.4 0.50.0 0.50.0 93.68.1 1.9 4.6 38.913.2 0.02 0.07
R(+)-alprenolol R(+)-metoprolol-d7 0.997 27.30.3 0.90.0 91.110.3 2.0 3.6 33.27.7 0.03 0.09
S()-atenolol S()-atenolol-d7 0.999 44.30.6 1.00.0 1.40.6 0.50.0 0.50.1 99.03.3 2.4 3.3 49.84.0 1.85 6.16
R(+)-atenolol R(+)-atenolol-d7 0.999 48.50.7 1.00.0 97.83.9 3.4 4.1 48.94.7 1.70 5.65
S(+)-citalopram S(+)-citalopram-d7 0.999 57.81.1 0.90.2 1.20.3 0.50.1 0.50.1 98.07.6 2.6 6.0 1.01.0 0.09 4.57
R()-citalopram R()-citalopram-d7 0.998 62.90.9 0.80.2 98.45.2 3.0 5.0 0.70.6 0.11 4.83
S(+)-desmethylcitalopram S(+)-citalopram-d7 0.997 55.70.5 0.80.2 4.01.5 0.50.0 0.50.0 101.17.0 2.0 7.1 25.94.6 0.12 0.41
R()-desmethylcitalopram R()-citalopram-d7 0.997 71.70.8 1.00.1 102.07.3 1.8 5.8 23.97.8 0.18 0.61
R()-desmethylvenlafaxine S()-propranolol-d7 0.998 28.70.5 0.90.0 1.40.5 0.50.1 0.70.2 92.512.2 1.9 10.4 44.75.1 0.19 0.62
S(+)-desmethylvenlafaxine R(+)-propranolol-d7 0.999 32.10.3 0.90.0 101.15.3 3.2 4.4 44.37.2 0.23 0.78
S(+)-ﬂuoxetine S()-propranolol-d7 0.999 39.80.3 1.30.0 1.20.2 0.50.0 0.50.1 96.47.7 2.4 7.5 5.61.0 0.01 0.04
R()-ﬂuoxetine R(+)-propranolol-d7 0.997 43.20.3 1.20.0 98.47.4 2.2 7.7 5.61.0 0.01 0.05
S()-metoprolol S()-metoprolol-d7 0.997 28.40.3 1.00.0 1.20.3 0.50.0 0.50.0 99.63.0 2.5 2.8 38.33.8 0.01 0.03
R(+)-metoprolol R(+)-metoprolol-d7 0.999 31.30.3 1.00.0 99.03.5 2.5 3.5 41.09.1 0.01 0.04
R()-mirtazapine R()-mirtazapine-d7 0.998 18.50.3 0.40.0 1.90.4 0.50.1 0.60.2 93.47.5 1.9 3.0 85.98.4 0.12 0.40
S(+)-mirtazapine S(+)-mirtazapine-d7 0.998 23.10.4 0.50.0 97.14.7 5.5 4.9 88.97.1 0.28 0.93
S(+)-norﬂuoxetine S()-propranolol-d7 0.958 32.40.3 1.00.0 0.60.1 0.40.1 0.50.2 124.538.1 5.3 20.5 0.37 1.25
R()-norﬂuoxetine R(+)-propranolol-d7 0.992 33.40.2 1.00.0 107.915.0 4.0 10.7 0.28 0.92
S()-propranolol S()-propranolol-d7 0.999 31.20.2 1.00.0 1.50.7 0.50.0 0.50.1 98.82.6 2.1 2.8 49.512.2 0.01 0.05
R(+)-propranolol R(+)-propranolol-d7 0.999 34.80.2 1.00.0 98.54.4 3.5 7.1 53.912.4 0.02 0.06
S(+)-salbutamol S()-propranolol-d7 0.999 23.10.3 0.70.2 1.20.4 0.50.0 0.60.2 100.46.1 2.0 6.3 34.82.3 0.13 0.45
R()-salbutamol R(+)-propranolol-d7 0.999 26.00.3 0.70.2 99.65.5 3.7 5.6 35.42.7 0.16 0.53
E1-sotalol E1-sotalol-d6 0.998 35.30.3 1.00.0 1.40.3 0.50.0 0.50.0 97.35.2 2.3 5.4 62.46.2 0.16 0.53
E2-sotalol E2-sotalol-d6 0.998 39.60.4 1.00.0 96.05.9 2.3 5.7 62.56.3 0.16 0.53
R()-terbutaline R(+)-propranolol-d7 0.997 28.40.2 0.90.2 2.32.1 0.50.1 0.50.2 113.427.1 6.0 22.8 47.115.4 1.35 4.51
S(+)-terbutaline S()-propranolol-d7 0.971 28.30.4 0.90.2 100.920.7 6.9 21.5 45.519.2 1.81 6.03
E1-tramadol R(+)-propranolol-d7 0.997 28.80.4 0.90.2 1.10.2 0.80.1 0.70.2 97.38.2 2.1 8.3 0.30.1 0.02 0.06
E2-tramadol S()-propranolol-d7 0.997 31.80.7 0.90.2 103.811.2 3.1 9.4 0.50.4 0.09 0.28
R()-venlafaxine R(+)-propranolol-d7 0.997 31.60.5 1.00.1 1.10.2 0.50.1 0.50.1 98.19.3 2.2 9.1 23.83.2 0.01 0.03
S(+)-venlafaxine S()-propranolol-d7 0.997 35.20.4 1.00.0 99.610.1 2.6 10.0 23.93.7 0.01 0.04
Note: (1) performance parameters (linearity retention time, resolution, enantiomeric fractions and ion ratios) were calculated for average values for the calibration protocol as awhole, above the ID.Whole calibration is 63 injections
in total (2) accuracy and precisionwere calculated for two concentrations 50 and 250mg L1; elution orders shown have either been demonstrated by comparing single enantiomer tr or assumed to be the same as in other published
work, using a comparable mobile phase and same column type. These are: alprenolol [38], citalopram, desmethylcitalopram [39], venlafaxine, desmethylvenlafaxine [40], metoprolol [41], mirtazapine [42], salbutamol [43] and
terbutaline [44]. Linearity range for individual compounds: IDL-250mg L1.
S.E.
 Evans
 et
 al.
 /
 A
nalytica
 Chim
ica
 A
cta
 xxx
 (2015)
 xxx
–
xxx
 
7
G
 M
o
d
el
A
C
A
 2
3
3
8
2
5
 N
o
.
 o
f
 P
ag
es
 1
5
Please
 cite
 th
is
 article
 in
 p
ress
 as:
 S.E.
 Evan
s,
 et
 al.,
 D
eterm
in
ation
 of
 ch
iral
 p
h
arm
aceu
ticals
 an
d
 illicit
 d
ru
gs
 in
 w
astew
ater
 an
d
 slu
d
ge
 u
sin
g
m
icrow
ave
 assisted
 extraction
,
 solid
-p
h
ase
 extraction
 an
d
 ch
iral
 liqu
id
 ch
rom
atograp
hy
 cou
p
led
 w
ith
 tan
d
em
 m
ass
 sp
ectrom
etry,
 A
n
al.
 C
h
im
.
A
cta
 (2015),
 h
ttp
://d
x.d
oi.org/10.1016/j.aca.2015.03.039
Table 5
Performance data for SPE-LC-MS/MS method - wastewater inﬂuent.
Compound tr tr rel Rs EFabs EFrel Precision RSD (%) Ion ratio Absolute SPE-LC-MS/MS
recovery (%)
Relative SPE-LC-MS/MS
recovery (%)
MDLcalc (ng L1) MQLcalc (ng L1)
Intra-day Inter-day
S()-alprenolol 24.40.2 0.90.0 0.90.1 0.50.0 0.50.1 8.08 6.1 37.60.8 98.120.6 159.339.7 0.07 0.24
R(+)-alprenolol 26.40.2 0.90.0 10.9 14.6 39.60.6 97.619.4 198.949.2 0.14 0.47
R()-amphetamine 22.20.2 1.00.0 1.10.1 0.50.0 0.50.0 2.4 5.5 90.52.1 78.711.9 107.81.2 0.38 1.28
S(+)-amphetamine 25.40.3 1.00.0 2.3 3.7 90.41.0 86.613.7 111.11.5 0.39 1.32
S()-atenolol 40.90.4 1.00.0 1.00.1 0.50.0 0.50.0 23.0 10.0 49.12.4 48.718.2 21.418.6 17.40 58.00
R(+)-atenolol 44.50.4 1.00.0 50.8 74.6 48.83.0 32.1412.1 19.58.8 28.74 95.81
S(+)-citalopram 52.20.9 0.90.0 1.00.1 0.80.2 0.80.2 9.0 9.7 1.00.2 174.949.2 91.914.1 0.24 13.07
R()-citalopram 56.71.1 0.90.0 6.2 10.0 0.90.2 176.437.3 95.111.4 0.31 13.69
S(+)-desmethylcitalopram 52.20.9 0.90.0 2.30.2 0.50.0 0.50.0 5.5 5.4 26.90.6 169.228.1 99.76.0 0.36 1.21
R()-desmethylcitalopram 56.71.1 0.90.0 9.1 10.7 27.40.9 181.629.5 102.410.6 0.50 1.68
R()-desmethylvenlafaxine 27.60.3 0.90.0 1.00.1 0.50.0 0.40.0 10.6 9.1 42.71.9 292.9179.2 142.621.3 0.32 1.05
S(+)- desmethylvenlafaxine 30.00.3 0.90.0 5.9 8.5 43.11.6 100.819.4 99.212.8 1.16 3.85
1S,2R(+)-ephedrine 18.50.2 0.80.0 20.01.6 0.50.1 0.50.1 2.3 4.5 7.92.7 61.46.6 120.221.0 0.16 0.02
1R,2S()-ephedrine 21.90.7 0.90.0 2.6 4.6 9.61.5 80.320.4 94.86.9 0.23 0.01
S(+)-ﬂuoxetine 37.90.3 1.40.0 1.00.1 0.50.0 0.60.0 9.3 9.8 5.80.1 88.613.7 120.422.1 0.07 0.22
R()-ﬂuoxetine 41.10.1 1.40.0 6.8 7.6 5.70.1 89.914.0 91.213.3 0.08 0.26
R()-MDA 33.30.4 1.00.0 1.30.1 0.50.0 0.50.0 3.2 3.2 24.20.6 80.810.8 100.62.1 0.33 1.13
S(+)-MDA 39.90.4 1.00.0 2.8 3.1 24.00.5 86.313.9 103.13.1 0.36 1.19
R()-MDMA 31.60.3 1.00.0 1.00.1 0.50.0 0.50.0 1.5 1.8 29.00.3 98.114.7 97.41.2 0.05 0.17
S(+)-MDMA 36.10.3 1.00.0 2.2 2.0 29.40.5 101.916.6 97.42.1 0.05 0.18
R()-methamphetamine 23.10.2 1.00.0 0.70.1 0.50.0 0.50.0 1.9 2.6 69.30.8 84.49.6 106.21.3 0.12 0.38
S(+)-methamphetamine 25.20.3 1.00.0 3.0 3.9 70.11.0 85.310.1 107.51.7 0.13 0.41
S()-metoprolol 27.20.2 1.00.0 1.00.1 0.40.0 0.50.0 2.2 2.2 38.40.6 85.613.8 87.24.7 0.06 0.18
R(+)-metoprolol 29.60.2 1.00.0 3.2 2.9 38.50.9 77.614.7 87.15.4 0.08 0.27
R()-mirtazapine 16.80.5 0.40.0 1.60.4 0.60.0 0.50.0 14.7 16.1 84.93.2 57.312.8 72.514.6 0.40 1.32
S(+)-mirtazapine 21.31.5 0.50.0 11.2 15.1 83.83.8 81.714.1 81.516.0 1.17 3.89
E1-norephedrine 18.70.2 0.80.0 7.50.3 0.30.1 0.50.0 10.0 15.1 4.00.3 50.35.8 86.38.7 0.33 0.01
E2-norephedrine 19.90.2 0.80.0 3.7 8.6 4.40.5 108.630.3 74.433.2 0.15 0.02
S()-propranolol 29.80.2 1.00.0 1.10.1 0.60.0 0.50.0 4.6 4.7 52.31.5 77.816.3 109.46.2 0.09 0.30
R(+)-propranolol 33.00.3 1.00.0 3.1 3.0 52.01.4 110.924.8 108.95.4 0.08 0.26
1R,2R()-pseudoephedrine 19.90.2 0.90.0 22.71.8 0.70.1 0.60.1 7.1 8.5 9.61.5 52.37.0 76.8510.2 0.26 0.01
1S,2S(+)-pseudoephedrine 22.90.2 0.90.0 5.1 9.2 12.31.2 143.663.6 56.63.83 0.10 0.03
S(+)-salbutamol 22.10.1 0.70.0 1.20.0 0.40.0 0.50.0 8.7 10.1 36.90.1 30.49.0 44.55.8 2.20 7.32
R()-salbutamol 25.00.2 0.80.0 12.4 14.7 38.10.9 35.711.1 51.412.5 2.22 7.41
E1-sotalol 33.50.3 1.00.0 1.10.1 0.50.0 0.50.0 2.2 6.5 59.52.5 120.426.5 94.87.9 0.66 2.20
E2-sotalol 37.40.3 1.00.0 7.6 4.4 56.92.4 130.430.8 94.39.9 0.61 2.05
E1-tramadol 28.10.3 0.90.0 0.80.0 0.60.0 0.60.0 8.9 12.7 0.30.0 99.128.0 138.834.1 0.09 0.29
E2-tramadol 30.00.3 0.90.0 6.8 11.5 0.40.0 99.716.7 102.415.5 0.43 1.43
R()-venlafaxine 30.10.6 1.00.0 1.10.1 0.50.0 0.50.0 4.6 8.2 23.11.1 99.764.4 148.336.3 0.03 0.11
S(+)-venlafaxine 33.10.6 1.00.0 2.7 8.5 22.51.6 108.269.8 112.437.3 0.04 0.12
Note: all performance parameters (retention time, resolution, accuracy, precision, ion ratios and SPE recoveries) were calculated for two concentrations 50 and 250ng L1 which were prepared in triplicate, n =6.
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Table 6
Performance data for SPE-LC–MS/MS method – wastewater efﬂuent.
Compound tr tr rel Rs EFabs EFrel Precision RSD (%) Ion ratio Absolute SPE-LC-MS/MS recovery (%) Relative SPE-LC-MS/MS recovery (%) MDLcalc
(ng L1)
MQLcalc
(ng L1)
Intra-day Inter-day
S()-alprenolol 24.90.1 0.90.0 1.00.0 0.50.0 0.50.0 6.8 6.0 37.50.5 252.432.5 187.331.1 0.03 0.09
R(+)-alprenolol 27.20.1 0.90.0 9.1 8.9 39.60.6 222.029.9 170.330.8 0.06 0.21
R()-amphetamine 25.32.6 1.00.0 1.10.1 0.50.0 0.50.0 4.7 6.8 89.32.2 107.435.3 100.729.2 0.28 0.94
S(+)-amphetamine 28.93.2 1.00.0 3.1 12.8 89.72.3 83.717.9 112.65.7 0.41 1.36
S()-atenolol 42.10.1 1.00.0 1.00.0 0.50.0 0.50.0 27.6 27.3 45.82.3 25.917.9 55.121.4 32.73 109.08
R(+)-atenolol 45.90.1 1.00.0 28.2 26.7 45.62.6 30.016.1 54.824.6 30.80 102.68
S(+)-citalopram 53.30.3 0.90.0 1.00.1 0.80.0 0.70.1 8.2 7.9 1.00.1 205.042.7 82.320.4 0.21 11.15
R()-citalopram 58.00.5 0.90.0 8.7 8.0 0.90.1 205.138.5 76.917.7 0.27 11.78
S(+)-desmethylcitalopram 53.30.3 0.90.0 2.40.3 0.50.0 0.50.0 8.7 8.4 27.30.4 212.133.3 73.218.2 0.29 0.96
R()-desmethylcitalopram 58.00.5 0.90.0 7.7 7.7 26.90.7 228.430.3 77.319.3 0.40 1.34
R()-desmethylvenlafaxine 28.20.1 0.90.0 1.00.0 0.50.0 0.50.0 25.5 23.2 41.31.3 240.635.2 124.121.5 0.38 1.28
S(+)-desmethylvenlafaxine 30.70.1 0.90.0 7.2 6.6 41.31.1 169.219.7 127.09.3 0.08 2.30
1S,2R(+)-ephedrine 22.20.3 0.80.0 26.31.2 0.50.0 0.60.0 5.5 16.7 10.50.8 132.214.6 120.121.0 0.07 0.25
1R,2S()-ephedrine 25.80.3 0.90.0 1.6 6.9 11.30.5 127.413.4 94.86.9 0.14 0.48
S(+)-ﬂuoxetine 39.10.1 1.40.0 1.00.0 0.50.0 0.50.0 25.0 22.7 5.80.1 139.219.8 108.722.6 0.04 0.14
R()-ﬂuoxetine 42.30.1 1.40.0 7.2 6.9 5.80.1 141.4222.7 108.316.2 0.05 0.17
R()-MDA 38.54.0 1.00.0 1.20.1 0.50.0 0.50.0 3.7 9.1 21.45.8 126.339.4 89.818.1 0.21 0.72
S(+)-MDA 44.75.5 1.00.0 3.9 8.7 23.12.4 123.539.2 96.927.9 0.25 0.83
R()-MDMA 36.44.0 1.00.0 0.90.1 0.50.0 0.50.0 2.2 7.2 27.71.5 134.742.1 89.218.6 0.04 0.13
S(+)-MDMA 41.04.7 1.00.0 2.8 6.2 27.21.8 124.339.2 99.239.1 0.04 0.14
R()-methamphetamine 26.62.8 1.00.0 1.00.0 0.50.0 0.50.0 5.7 10.4 67.92.0 114.437.3 102.915.1 0.09 0.28
S(+)-methamphetamine 29.03.0 1.00.0 3.7 10.9 68.41.8 130.844.8 109.36.1 0.08 0.27
S()-metoprolol 27.90.1 1.00.0 1.00.1 0.50.0 0.50.0 7.7 6.4 37.90.9 131.216.3 87.24.7 0.04 0.12
R(+)-metoprolol 30.40.1 1.00.0 7.7 6.5 38.00.9 138.115.1 86.27.0 0.05 0.15
R()-mirtazapine 16.70.1 0.50.0 1.40.1 0.50.0 0.50.0 8.9 9.5 80.43.1 150.425.7 105.824.1 0.40 1.32
S(+)-mirtazapine 20.60.2 0.50.0 8.2 8.3 81.53.7 163.430.3 120.117.2 0.86 2.86
E1-norephedrine 22.40.3 0.80.0 10.11.3 0.60.1 0.60.1 3.3 26.1 21.20.8 87.217.1 86.38.7 0.19 0.63
E2-norephedrine 23.70.3 0.80.0 2.3 59.4 17.511.1 76.212.0 74.433.2 0.21 0.71
S()-propranolol 30.70.1 1.00.0 1.10.1 0.50.0 0.50.0 9.1 7.7 53.21.0 136.215.1 108.89.9 0.05 0.17
R(+)-propranolol 33.00.3 1.00.0 6.9 5.7 53.51.0 147.117.2 110.68.1 0.06 0.20
1R,2R()-
pseudoephedrine
23.80.2 0.90.0 25.22.3 0.40.0 0.40.0 3.5 14.0 11.00.3 89.27.0 76.910.2 0.15 0.52
1S,2S(+)-
pseudoephedrine
27.20.3 0.90.0 2.8 14.0 9.51.8 133.046.2 56.63.8 0.11 0.36
S(+)-salbutamol 22.80.1 0.70.0 1.20.0 0.50.0 0.50.0 5.7 6.0 37.70.9 68.412.2 46.920.9 0.98 3.26
R()-salbutamol 25.60.1 0.80.0 5.6 5.0 38.10.9 60.713.9 64.213.6 1.31 4.36
E1-sotalol 34.50.1 1.00.0 1.20.1 0.40.0 0.50.0 8.2 8.6 56.22.0 151.121.9 94.88.1 0.53 1.76
E2-sotalol 38.50.1 1.00.0 8.4 8.4 56.92.4 174.124.6 94.310.9 0.46 1.53
E1-tramadol 28.70.1 0.90.0 0.80.0 0.50.0 0.40.1 8.3 8.3 0.30.0 172.926.0 136.029.0 0.05 0.16
E2-tramadol 30.70.1 0.90.0 7.4 9.0 0.40.0 179.621.3 142.014.3 0.24 0.79
R()-venlafaxine 30.40.1 1.00.0 1.00.1 0.50.0 0.50.0 8.3 9.2 21.61.0 220.420.5 132.122.8 0.02 0.07
S(+)-venlafaxine 33.30.2 1.00.0 8.8 11.3 21.61.0 177.729.8 117.643.1 0.03 0.11
Note: all performance parameters (retention time, resolution, accuracy, precision, ion ratios and SPE recoveries) were calculated for two concentrations 50 and 250ng L1 which were prepared in triplicate, n =6.
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Table 7
Performance data for MAE-SPE-LC-MS/MS method – digested sludge (1 g).
Compound tr tr rel Rs EFabs EFrel Precision RSD (%) Ion ratio Absolute MAE-SPE-LC-MS/MS
recovery (%)
Relative MAE-SPE-LC-MS/MS
recovery (%)
MDLcalc
(ng g1)
MQLcalc
(ng g1)
Intra-day Inter-day
S()-alprenolol 28.40.1 0.90.0 1.30.1 0.40.0 0.50.0 15.2 15.9 37.91.9 15.00.9 82.710.2 0.14 0.46
R(+)-alprenolol 31.10.2 0.90.0 10.2 22.5 67.93.2 19.31.8 85.02.2 0.14 0.48
R()-amphetamine 26.50.4 1.00.0 2.90.3 0.50.0 0.50.0 13.2 11.6 88.15.1 6.13.1 77.110.2 4.92 16.56
S(+)-amphetamine 30.40.5 1.00.0 15.2 13.1 89.46.9 6.61.9 75.510.0 5.15 17.28
S()-atenolol 44.07.8 1.00.2 1.40.3 0.50.1 0.50.1 16.3 35.0 0.40.2 26.09.2 25.819.1 7.12 23.70
R(+)-atenolol 48.28.6 1.00.2 32.7 45.9 2.61.0 24.510.1 18.611.5 7.55 25.15
S(+)-citalopram 71.10.9 1.00.0 1.10.1 0.60.0 0.60.0 10.2 24.8 1.30.2 97.521.9 137.679.7 0.09 4.69
R()-citalopram 75.05.3 1.00.0 8.4 22.1 1.40.1 53.214.1 98.054.8 0.21 9.09
S(+)-desmethylcitalopram 61.50.5 0.80.0 2.60.1 0.50.2 0.60.1 8.3 25.2 3.90.1 33.57.8 55.636.0 0.36 1.22
R()-desmethylcitalopram 76.40.7 0.90.0 6.2 7.2 3.80.2 30.614.5 26.22.0 0.42 1.99
R()-desmethylvenlafaxine 34.40.3 1.00.0 0.90.0 0.50.0 0.50.0 10.3 35.7 41.41.6 24.63.8 114.534.0 0.75 2.51
S(+)-desmethylvenlafaxine 36.80.3 0.90.0 11.2 14.5 40.82.6 22.83.0 108.524.9 1.02 3.41
1S,2R(+)-ephedrine 27.70.0 0.80.0 2.60.3 0.80.1 0.70.1 32.9 30.7 9.52.1 – – – –
1R,2S()-ephedrine 30.50.0 0.90.0 14.3 72.3 15.33.3 – – – –
S(+)-ﬂuoxetine 45.40.3 1.30.0 1.20.0 0.60.0 0.20.0 10.3 19.3 5.80.1 17.13.6 9.02.6 0.07 0.23
R()-ﬂuoxetine 49.40.4 1.20.0 9.6 32.8 5.70.4 15.73.1 47.98.5 0.09 0.30
R()-MDA 40.00.7 1.00.0 4.20.3 0.50.0 0.50.0 10.8 10.5 26.31.7 12.23.6 67.27.0 2.21 7.46
S(+)-MDA 47.70.9 1.00.0 8.1 7.7 25.42.6 7.53.1 68.35.6 4.14 13.74
R()-MDMA 38.30.7 1.00.0 1.20.1 0.50.0 0.50.0 5.7 7.2 30.62.5 21.75.9 71.63.9 1.43 4.75
S(+)-MDMA 43.70.8 1.00.0 9.2 8.2 30.92.5 17.36.7 71.26.4 1.79 5.96
R()-methamphetamine 28.00.5 1.00.0 1.90.2 0.50.0 0.50.0 6.0 5.1 70.01.4 13.74.3 84.44.8 0.73 2.34
S(+)-methamphetamine 30.90.5 1.00.0 7.8 6.7 68.91.7 14.34.4 83.76.2 0.77 2.45
S()-metoprolol 31.90.2 1.00.0 1.20.1 0.40.0 0.50.0 10.9 17.6 37.71.1 14.31.1 103.014.1 0.07 0.22
R(+)-metoprolol 35.10.2 1.00.0 10.7 17.8 38.30.7 27.12.5 105.715.6 0.05 0.15
R()-mirtazapine 25.20.4 0.70.0 2.70.2 0.50.0 0.30.0 11.4 17.8 83.51.3 39.16.5 243.3115.4 0.31 1.02
S(+)-mirtazapine 34.10.7 0.90.0 4.3 35.2 84.55.0 38.44.5 172.973.0 0.73 2.44
E1-norephedrine 27.70.0 0.80.0 0.80.1 0.50.0 0.60.0 33.4 28.2 25.62.3 17.216.4 119.9103.9 9.54 31.52
E2-norephedrine 30.50.0 0.80.0 32.2 27.4 23.53.2 12.512.7 86.679.3 13.05 43.38
S()-propranolol 35.10.3 1.00.0 1.40.1 0.50.0 0.50.0 9.1 23.1 53.50.6 23.63.1 93.58.7 0.06 0.20
R(+)-propranolol 39.50.2 1.00.0 5.8 20.5 56.20.8 25.84.7 105.09.2 0.07 0.23
1R,2R()-pseudoephedrine 27.70.0 0.90.0 1.70.1 0.70.1 0.70.1 23.6 22.4 13.31.6 9.44.2 94.018.4 15.54 51.62
1S,2S(+)-pseudoephedrine 30.50.0 0.90.0 12.1 24.7 13.82.9 3.10.6 44.15.4 44.53 148.5
S(+)-salbutamol 25.60.2 0.70.0 1.90.2 0.50.0 0.60.1 20.5 51.7 37.15.3 0.20.0 0.80.2 65.03 225.1
R()-salbutamol 29.00.2 0.70.0 45.1 47.7 41.76.2 0.20.0 0.50.2 80.03 265.1
E1-sotalol 40.00.3 1.00.0 1.50.1 0.50.0 0.50.2 8.1 28.6 58.62.9 9.72.7 122.011.4 1.64 5.47
E2-sotalol 44.70.3 1.00.0 9.4 34.2 55.92.1 9.12.7 142.920.2 0.76 5.87
E1-tramadol 34.70.3 1.00.0 0.80.0 0.80.0 0.60.0 12.9 41.7 0.30.0 31.610.4 209.341.1 0.05 0.18
E2-tramadol 36.80.4 0.90.0 13.3 21.9 0.40.1 25.32.9 323.747.0 0.34 1.13
R()-venlafaxine 37.60.4 1.10.0 1.00.0 0.50.0 0.40.0 14.4 24.5 20.51.0 37.54.7 137.036.0 0.03 0.08
S(+)-venlafaxine 40.50.4 1.00.0 14.3 22.1 20.10.9 48.57.1 183.037.3 0.03 0.08
Note: all performance parameters (retention time, resolution, accuracy, precision, ion ratios and MAE recoveries) were calculated for two concentrations 50 and 100ng g1 which were prepared in triplicate, n =6.
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Fig. 2. Mass chromatograms of chiral drugs present in wastewater inﬂuent analysed with CBH column.
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ACA 233825 No. of Pages 15was 100% methanol, 0.005% formic acid and 4 mM ammonium
acetate.
In general the method development results highlight how
longer retention times can produce better resolution, however,
these two factors must be balanced in order to maintain a practical
analytical technique, the current method for the target analytes is
80 min long. Although many iterations of additives and mobile
phases were trialled, and trends were noted, none of the
compounds previously unsuccessfully resolved with methanol,
0.005% formic acid and 4 mM ammonium acetate could be brought
to above the relevant quantiﬁcation thresholds and the method
therefore remained unchanged.
The optimised chromatographic conditions used for separation
of enantiomers in Chirobiotic V utilised a mobile phase composed
of methanol, 0.005% formic acid and 4 mM ammonium acetate.
Separations were undertaken under isocratic conditions and a ﬂow
rate of 0.1 mL min1. The column temperature was 25 C and the
injection volume was 20 mL (Fig. 1).
The following compounds were separated with this column:
alprenolol, atenolol, citalopram, desmethylcitalopram, desmethyl-
venlafaxine, ﬂuoxetine, metoprolol, mexiletine, mirtazapine,
propranolol, salbutamol, sotalol, terbutaline, tramadol and ven-
lafaxine (Figs. S3–5).
3.3. Validation of analytical methods
3.3.1. Validation of instrumental parameters
Results of the calibration curves are detailed in Table 4. Good
linearity of response (R2 0.997) within the studied concentration
range was achieved for most compounds with the exception of
terbutaline and norﬂuoxetine. These analytes consistently fell
outside of tolerance limits set and will therefore not be considered
further (results are included in the relevant table for illustrative
purposes only).
Resolution (Rs 1.00) was also achieved for all the enantiomers
except MDEA (Rs = 0.59–0.65), norephedrine (0.81–0.94) and
norﬂuoxetine (0.83–0.87). For a few compounds, includingPlease cite this article in press as: S.E. Evans, et al., Determination of chir
microwave assisted extraction, solid-phase extraction and chiral liquid ch
Acta (2015), http://dx.doi.org/10.1016/j.aca.2015.03.039methamphetamine, desmethylvenlafaxine, ﬂuoxetine and citalo-
pram, higher concentrations, resulting in larger peak areas,
resulted in reduced resolution, however, this effect is considered
to be negligible at environmentally relevant concentrations.
Absolute EF values were usually within the range of 0.45–0.55 with
the exception of amphetamine, ephedrine, norﬂuoxetine and
tramadol, however, all of these were brought to within this range
when average relative EF values were calculated, with the
exception of tramadol. However, several compounds’ relative
enantiomeric fractions were not between 0.45 and 0.55, although
their absolute enantiomeric fractions were. These include salbu-
tamol, mirtazapine and desmethylvenlafaxine. Accuracy was good
throughout and both inter- and intra-day precision was generally
<10%. The ion ratio standard deviations were consistently well
within tolerance limits set for all compounds. IDLs were usually
between 0.01 and 1.83 mg L1 and IQLs between 0.03 and 1.16 mg
L1.
3.3.2. Validation of analytical methods
Almost all of the compounds were successfully calibrated,
passing all of the criteria set out in Section 2.5, only exceptions
were MDEA, terbutaline and norﬂuoxetine which were therefore
not carried forward to validation. These three compounds all suffer
from poor chromatographic resolution. Terbutaline co-eluted with
another similarly structured compound resulting in multiple,
overlapping peaks which impacted identiﬁcation and quantiﬁca-
tion. MDEA and norﬂuoxetine did not achieve adequate resolution.
During method development it was known that norﬂuoxetine
requires 10% water in the mobile phase to achieve good
enantiomeric resolution, however, this had signiﬁcant impacts
on the resolution and sensitivity of many other compounds,
therefore, this compound could not be analysed alongside the
other compounds resolved by the Chirobiotic V.
3.3.2.1. SPE-chiral LC–MS/MS. Results for the validation of the SPE-
chiral LC–MS/MS method in wastewater inﬂuent and efﬂuent can
be found in Tables 5 and 6, respectively. In brief, the retention timeal pharmaceuticals and illicit drugs in wastewater and sludge using
romatography coupled with tandem mass spectrometry, Anal. Chim.
Fig. 3. Mass chromatograms of chiral drugs in wastewater inﬂuent analysed with Chirobiotic V column.
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ACA 233825 No. of Pages 15for all the compounds from the liquid matrices is not impacted by
more than 4 min compared to sample diluent, except in the cases of
citalopram, desmethylcitalpram and MDA in inﬂuent and efﬂuent
as well as S(+)-MDMA and S(+)-amphetamine in inﬂuent only.
Changes in retention times were compensated for by using internal
standards (see relative retention times in Tables 5 and 6).
Enantiomeric resolution was maintained above 1 for all
compounds at the three studied concentrations in wastewater
inﬂuent and efﬂuent except alprenolol (Rs = 0.9), MDMA (Rs = 0.9),
tramadol (Rs = 0.8) and methamphetamine (Rs = 0.7). In order to
undertake quantiﬁcation of enantiomers, their resolution has to be
1. Therefore, compounds having Rs< 1 were treated on a semi-
quantitative basis.
Several absolute EFs deviated from 0.5, however, their relative
EF values were close to 0.5, with the exception of citalopramPlease cite this article in press as: S.E. Evans, et al., Determination of chi
microwave assisted extraction, solid-phase extraction and chiral liquid ch
Acta (2015), http://dx.doi.org/10.1016/j.aca.2015.03.039(EF = 0.8), tramadol (0.6), desmethylvenlafaxine (0.4) in inﬂuent,
as well as citalopram (0.7) and pseudoephedrine (0.4) in efﬂuent.
In addition, although their absolute EF values were close to 0.5,
desmethylvenlafaxine (0.4) and ﬂuoxetine (0.6) EF values
deviated from racemic in inﬂuent and ephedrine (0.6) and
tramadol (0.4) in efﬂuent. No deuterated analogues were
available for these compounds and this result suggests that
although there is no stereoselective degradation of the target
analytes stereoselective matrix effects do appear to have occurred
in the internal standard and therefore impacted the relative
enantiomeric fraction. Interday and intraday precision for both
matrices was high, ranging from 1.5% (MDMA) to 74.6% (atenolol),
although most were less than 10%. Relative ion intensities were
consistently within tolerance levels for both wastewater inﬂuent
and efﬂuent.ral pharmaceuticals and illicit drugs in wastewater and sludge using
romatography coupled with tandem mass spectrometry, Anal. Chim.
Table 8
Wastewater analysis.
Compound Inﬂuent Efﬂuent Digested sludge
Concentration (ng L1) EF Concentration (ng L1) EF Concentration (ng g1) EF
Alprenolol 220.7  2.1b 0.5  0.0b 202.0  5.7b 0.5  0.0b 19.8  6.1 0.7  0.2
Amphetamine 280.3  4.1 0.5  0.0 22.0  0.0 0.6  0.0 7.9  1.7 0.3  0.1
Atenolol 447.0  18.3 0.5  0.0 76.5  4.9 0.5  0.0 2.4  1.2 0.4  0.0
Citalopram 650.0  50.0 0.6  0.0 53.0  3.7 0.7  0.0 121.0  60.2 0.6  0.0
Desmethylcitalopram 2.3  0.9 1.0  0.0 <MDL – 167.0  29.0b 0.6  0.1b
Desmethylvenlafaxine 706.7  18.6 0.5  0.1 288.7  11.4 0.5  0.0 18.4  6.4 0.5  0.0
Ephedrine 20.2  28.6 0.0  0.0 1.3  0.2 0.0  0.0 <MDLb –
Fluoxetine 51.0  4.3 0.7  0.0 26.0  0.0 0.7  0.0 85.6  9.4b 0.7  0.1b
MDA 17.0  1.4 0.6  0.0 42.7  1.3 0.5  0.0 2.2  0.6 0.3  0.0
MDMA 34.3  1.3 0.7  0.0 45.3  0.5 0.9  0.0 16.3  0.7 0.4  0.0
Methamphetamine 34.0  1.41 0.6  0.0 28.0  0.0 0.5  0.0 3.18  0.5 0.5  0.1
Metoprolol 1.7  0.5 0.3  0.2 <MDL – 0.4  0.1 0.3  0.3
Mirtazapine 117.3  3.7 0.3  0.0 64.0  2.5 0.2  0.0 217.2  89.4b 0.5  0.1b
Norephedrine 359.3  56.3 0.0  0.0 52.7  2.1a 0.3  0.0a 48.9  33.4b 0.1  0.1b
Propranolol 105.0  0.8 0.4  0.0 35.3  0.9 0.4  0.0 59.9  9.7 0.5  0.1
Pseudoephedrine 479.7  28.5 1.0  0.0 30.0  0.2a 0.2  0.1a <MDLb –
Salbutamol 284.7  27.9 0.5  0.0 460.7  11.5 0.5  0.0 <MDLb –
Sotalol 245.7  19.6 0.5  0.0 146.3  9.0 0.5  0.0 6.7  3.4 0.5  0.1
Tramadol 1320.7  59.3 0.7  0.1 506.0  46.6 0.7  0.0 30.5  7.7 0.7  0.1
Venlafaxine 352.7  29.5 0.5  0.0 220.3  17.3 0.5  0.0 83.2  18.5 0.5  0.1
Samples prepared in triplicate and injected in triplicate, n = 9.
a One of the enantiomers was <MQL and should be treated on a semi-quantitative basis.
b The compound did not pass all the validation criteria and should be considered semi-quantitative.
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tamol) to 292.9% (desmethylvenlafaxine). Relative SPE recoveries
in inﬂuent were all adequate between 56.6% (pseudoephedrine)
and 138.8% (tramadol), although there were three exceptions:
alprenolol (159.3 and 198.9% for each enantiomer), atenolol
(21.4 and 19.5% for each enantiomer) and salbutamol (46.9 and
51.4% for each enantiomer). Efﬂuent absolute SPE recoveries
ranged between 25.9% (atenolol) and 252.4% (alprenolol). Several
of the absolute recoveries were greater than 150%, although the
corresponding relative recoveries were much lower suggesting
signiﬁcant ion enhancement took place. This was not the case in
the inﬂuent which highlights the importance of validating all types
of matrices to be analysed as large discrepancies can occur
between comparable matrices and relatively cleaner matrices
should not be assumed to pose fewer challenges for analysis.
Relative SPE recoveries were generally acceptable, ranging
between 56.4% (pseudoephedrine) and 142.0% (tramadol), the
only exceptions to this range was atenolol (55.1% and 54.8 for each
enantiomer), alprenolol (187.3% and 170.3% for each enantiomer)
and salbutamol (46.9 and 64.2 for each enantiomer). There are
some cases of absolute recoveries being quite different between
enantiomers. This is thought to be a result of temporal separation
during the chromatography followed by ion suppression and/or
enhancement of one or both of the enantiomers.
Ion ratios for all the compounds in the liquid matrices are
within the thresholds suggesting no co-eluting compounds are
compromising the analysis. MDLs in wastewater inﬂuent were
between 0.05 ng L1 and 28.74 ng L1, MQLs ranged from 0.03 ng
L1 to 95.81 ng L1. MDLs in wastewater efﬂuent were between
0.01 ng L1 and 32.73 ng L1, MQLs ranged from 0.07 ng L1 to
109.08 ng L1. The majority of MDLs and MQLs were below
1 ng L1, isolated cases, notably atenolol, citalopram and salbu-
tamol, were signiﬁcantly high though. The MQLs in the liquid
matrices are all suitable for wastewater analysis, illustrating that
despite a complex matrix this sample preparation and analytical
method are suitable for wastewater concentrations of this
magnitude.
The validation of the analytical method illustrates that the
sample preparation methods chosen are appropriate.Please cite this article in press as: S.E. Evans, et al., Determination of chir
microwave assisted extraction, solid-phase extraction and chiral liquid ch
Acta (2015), http://dx.doi.org/10.1016/j.aca.2015.03.0393.3.2.2. MAE–SPE-chiral LC–MS/MS. Results for the MAE-chiral
LC–MS/MS validation using 1 g of matrix are detailed in Table 7.
Ephedrine, pseudoephedrine and norephedrine all suffered from
several issues including poor accuracy and precision and they are
not considered validated for this method; the results are included
for illustrative purposes only, in addition salbutamol’s recovery
was insufﬁcient to be quantiﬁable. In brief, the retention times are
impacted by this matrix and/or the method more than for the
liquid matrices, however, due to the use of surrogate standards,
changes in retention times are compensated for. Five compounds’
EF values deviated from racemic in solid matrices including
citalopram and desmethylcitalopram (0.6), mirtazapine (0.3),
ﬂuoxetine (0.2), tramadol (0.6) and venlafaxine (0.4). Intraday
precision ranged between 4.3 and 33.4%, however, was generally
below 15%. Inter-day precision ranged between 5.1 and 45.9%,
although was generally less than 30%. Relative ion intensities were
consistently within tolerance levels. Absolute recoveries are
generally, relatively low, often between 10% and 50%, however,
most relative recoveries were between 65% and 140%, exceptions
however include atenolol (25.8 and 18.6% for each enantiomer),
desmethylcitalopram (55.6 and 26.2% for each enenatiomer),
ﬂuoxetine (9.0 and 47.9% for each enantiomer), mirtazapine (243.3
and 172.9% for each enantiomer), and tramadol (209.3 and 323.7%
for each enantiomer). Compounds in standard solutions were also
passed through the cartridges without matrix (Table S3) which
conﬁrmed that the MAX cartridges are poor at retaining and/or
eluting these compounds.
The sample preparation was suitable to remove co-eluting
compounds whilst maintaining the resolution at a variety of
concentrations. The cartridges, as discussed above, do not retain
and/or elute the basic compounds efﬁciently, resulting in poor
absolute recoveries. However, despite this, the majority are well
compensated for by their internal standards, highlighting the
importance of these internal standards. Compounds which do not
meet the standards set for relative recoveries and/or relative
enantiomeric fractions did not have direct deuterated analogues as
surrogate standards, and therefore these discrepancies may be
addressed with the introduction of new surrogate standards (if
available), being direct deuterated or C13-analogues of targetal pharmaceuticals and illicit drugs in wastewater and sludge using
romatography coupled with tandem mass spectrometry, Anal. Chim.
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ranging from 0.080 ng g1 (S(+)-venlafaxine) to 25.2 ng g1
(R(+)-atenolol), appear to be appropriate for the concentrations
found in the sludge samples suggesting the sample size chosen is
adequate.
3.4. Wastewater analysis
The methods described above were applied to inﬂuent and
efﬂuent wastewater and digested sludge, and represent the ﬁrst
example of analysis of a suite of compounds from all three matrices
in the wastewater treatment system at the enantiomeric level.
Mass chromatograms of chiral drugs present in wastewater
inﬂuent and analysed with both CBH and Vancomycin V columns
are shown in Figs. 2 and 3 as examples. Concentrations in the
inﬂuent ranged between 1.7 ng L1 (metoprolol) and 1320.7 ng L1
(tramadol), however, efﬂuent levels appeared to be lower for all
compounds apart from MDA, MDMA and salbutamol (Table 8). The
samples were all taken simultaneously, so it is impossible to
comment on removal rates as they do not represent the same body
of wastewater as it ﬂows through the WWTP. However, the results
do indicate that even closely related compounds do not appear to
have similar degradation pathways. For example, atenolol and
sotalol appear at relatively high concentrations in the inﬂuent and
efﬂuent, with little having been adsorbed to the digested sludge,
whereas a relatively high concentration of propranolol has
adsorbed to the digested sludge.
Enantiomeric fractions of ten compounds in the inﬂuent
signiﬁcantly varied from the EF recorded in the validation,
suggesting human metabolism and biological action within the
sewerage system had altered the enantiomeric fraction from the
either racemic or single enantiomer ingested drug. In the efﬂuent,
after the biological action of activated sludge, EFs of 8 compounds
were signiﬁcantly different from those measured in a racemic
mixture. Nine compounds: amphetamine, desmethylcitalopram,
ephedrine, MDA, MDMA, methamphetamine, mirtazapine, nor-
ephedrine and pseudoephedrine had signiﬁcantly different EF
values in the inﬂuent and efﬂuent, which indicates stereoselective
processes occurring during activated sludge treatment.
The digested sludge, which had undergone activated sludge
action and anaerobic digestions as well, contained all the validated
compounds at quantiﬁable concentrations, except ephedrine,
pseudoephedrine and salbutamol; concentrations ranged from
0.4 ng g1 (metoprolol) to 275.2 ng g1 (citalopram) even though
many are polar. This analysis of digested sludge does highlight the
potential for an overestimation in the success rate of activated
sludge removing pharmaceuticals, such as in the cases of
citalopram and ﬂuoxetine where low concentrations are found
in the efﬂuent, however, relatively high concentrations are in the
digested sludge. For the ﬁrst time the examination of the
enantiomeric fraction of these compounds in the solid matrices
indicates that EFs for four compounds (alprenolol, MDA, MDMA,
norephedrine and tramadol) signiﬁcantly deviated from the
racemic EF. In addition 9 compounds analysed had signiﬁcantly
different EFs in the efﬂuent and the digested sludge demonstrating
that biological processes which occur in the sludge, either during
activated sludge treatment or during anaerobic digestion, result in
a different EF when compared to the one in the water fraction. This
indicates that either differing microorganism populations or the
change in conditions instigates a different metabolic pathway
which results in a different EF. It is worth noting that different
microbial communities are present during aerobic activated sludge
treatment and anaerobic digestion and therefore different stereo-
selective metabolic pathways were expected in this work. This is
particularly stark in comparing efﬂuent and digested sludge
enantiomeric fractions of MDA (0.5 and 0.3, respectively), MDMAPlease cite this article in press as: S.E. Evans, et al., Determination of chi
microwave assisted extraction, solid-phase extraction and chiral liquid ch
Acta (2015), http://dx.doi.org/10.1016/j.aca.2015.03.039(0.9 and 0.4, respectively), alprenolol (0.5 and 0.7) and mirtazapine
(0.2 and 0.5, respectively). Further work is currently being
undertaken to understand stereoselective degradation of chiral
PACs during wastewater treatment.
4. Conclusions
This work has demonstrated for the ﬁrst time a method which
can identify and quantify a range of chiral pharmaceuticals and
illicit drugs at enantiomeric level from wastewater inﬂuent,
efﬂuent and digested sludge. These methods were evaluated
through a series of parameters recommended by the EC Directive
[37] and in addition the resolution and enantiomeric fraction, both
absolute and relative, were assessed. To the authors’ knowledge
this is also one of the most rigorous validation tests of chiral
wastewater analysis published to date. A combination of excellent
instrument sensitivity, concentration steps within the sample
preparation and good recoveries have resulted in low quantiﬁca-
tion levels within the anticipated environmental range.
Based on the results above, the following compounds are
considered to have been successfully calibrated and validated for
all three matrices: amphetamine, methamphetamine, MDMA,
MDA, venlafaxine, desmethylvenlafaxine, citalopram, metoprolol,
propranolol and sotalol. Mirtazapine, salbutamol, ﬂuoxetine,
desmethylcitalopram, atenolol, ephedrine and pseudoephedrine
passed all validation criteria in liquid matrices, although in solid
matrices they did not pass all the criteria and should be considered
on a semi-quantitative basis only. In addition, alprenolol did not
pass all the criteria in the liquid matrices and should be considered
semi-quantitative in this matrix, although fully quantitative in the
solid matrix.
The results indicate that chiral PACs are present in all
wastewater matrices and that the EF values are often not racemic,
suggesting current risk assessment procedures assessing whole
drugs for toxicity in environmental matrices may not be
appropriate, and that biological wastewater treatments are
capable of changing the enantiomeric fraction.
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